OncoSignal
Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma

Ewing sarcoma

An EWSR1 fusion-driven sarcoma of children and young adults; relapsed disease has few options.

Live from ClinicalTrials.gov and PubMed, fetched 2026-11-11 15:25 UTC. Every row links to its source record.

Registry changes (new trials, status, phase, endpoint and readout-date changes, results) come from the OncoSignal store, last verified against ClinicalTrials.gov 2026-11-11 08:26 UTC.

Phase advances
0
since 2026-07-14
New Ph2+ trials
0
Results posted
1
Readouts due
0
primary completion reached
Trial papers
2
PubMed, last 60 days
  1. Results posted
    Results posted: NCT05275426

    A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor

  2. Paper
    Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53, STAG2, and CDKN2A Alterations.

    Mous L, Ballet S, Dureau S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

    Publisher page
  3. Paper

A phase advance is an asset's first trial at a higher phase than any earlier trial of the same asset in this indication. Readout due means the registry's primary completion date has passed; it is not a disclosure.